Skip to main content

Cardiology Information System (CIS) Market (WITH IMPACT OF COVID-19) | End User (L3A Hospital, L3B and L2 Hospital)

Growth in this market is mainly driven by the increasing incidence and prevalence of cardiovascular disease, government initiatives in China, and the increasing number of hospitals.

  • The China cardiology information system market is projected to reach $54 million by 2024 from $35 million in 2019, at a CAGR of 8.9% during the forecast period.

Cardiology Information System (CIS) Market by System (Standalone, Integrated System, Cardiology Information System, Cardiology PACS), Component (Software, Services, Hardware), & End User (L3A Hospital, L3B and L2 Hospital) – China Forecast to 2024

The software segment accounted for the largest share of the China cardiology information system market in 2018

By component, the market is segmented into software, services, and hardware. The software segment accounted for the largest market share in 2018. The large share of this segment can be attributed to the growing need to integrate CVIS with C-PACS, EMRs, and other cardiology modules.

Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=264168583


1.China Cardiology Information System Market, by System

  • Integrated Systems
  • Standalone Systems

2. China Cardiology Information System Market, by Component

  • Software
  • Services
  • Hardware

3. China Cardiology Information System Market, by End User

  • L3A Hospitals
  • L3B and L2 Hospitals

The integrated systems segment is expected to grow at the highest CAGR during the forecast period

Based on system, the market is segmented into integrated and standalone systems. The integrated systems segment is projected to witness the highest growth during the forecast period. The increasing adoption of integrated systems by healthcare providers is the major factor supporting the growth of this segment.

Request for Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=264168583

L3A hospitals accounted for the largest share of the China cardiology information system market in 2018

Based on end user, the market is segmented into L3A hospitals and L3B & L2 Hospitals. The L3A hospitals segment accounted for the largest share of the market in 2018. The increasing number of L3A hospitals in China and growing disease prevalence are responsible for the large share of this market segment.

Some key players mentioned in the research report are:

Key players in the China cardiology information system market are Philips Healthcare (Netherlands), CREALIFE Medical Technology (China), Central Data Network (Australia), Infinitt Healthcare (South Korea) and Esaote (Italy).

In 2018, CREALIFE Medical Technology held the leading position in the market. The company has good relations with government bodies, distributors, and hospitals in the market, which is its key strength. Philips Healthcare held the second position in the market in 2018.

Labels:

Comments

Post a Comment

Popular posts from this blog

Inspection Machines Market To Reach USD 871 Million By 2025 - Growing Demand For Personalized Medicine

  What This Report Will Provide? This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies. Expected Revenue Growth: The  Inspection machines market  is projected to reach USD 871 million by 2025 from USD 671 million in 2020, at a CAGR of 5.4% during the forecast period. Major Growth Boosters: The growth of this market is majorly driven as companies are now increasingly adopting inspection systems throughout their production lines due to the growing concerns to the regulatory mandates introduced by the government and regulatory bodies in the healthcare industry to maintain compliance with Good Manufacturing Practices ( GMP ). Download PDF Brochure:    https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81453085   CO...
Post a Comment
Read more

Health Information Exchange (HIE) Market Worth USD 2.0 Billion By 2025 : Growing Adoption Of EHRs

  What This Report Will Provide?  This study involved four major activities in estimating the size of the health information exchange market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. Expected Revenue Growth: [199 Pages Report]  The  global health information exchange market  is expected to reach USD 2.0 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 12.2%. Major Growth Boosters: Growth in this market can be attributed to factors such as growing need to curtail healthcare costs, focus on patient-centric care delivery, growing adoption of EHRs and other HCIT solutions, government initiatives for enhancing patient care and safety, government funding for healthcare interoperabilit...
Post a Comment
Read more

Biologics Safety Testing Market To Reach USD 4.90 Billion By 2022 : Increasing Pharmaceutical Outsourcing

  What This Report Will Provide? Biologics are pharmaceutical products that are extracted from biological sources. Biologics safety testing is carried out by manufacturers to detect contaminants like bacterial toxins, mycoplasma, and viruses. It is a mandatory process in these companies for the quality control of raw materials as well as for process control and validation of end products. Expected Revenue Growth: The global  biologics safety testing market  is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% during forecast period. Major Growth Boosters: The major factors driving the growth of this market are the growth in pharmaceutical & biotechnology industry driven by government support, the positive trend of R&D investment in the life science sector, increasing number of drug launches, and high incidence & large economic burden of chronic diseases. In the coming years, emerging markets and increasing pharmaceuti...
Post a Comment
Read more